Bernstein Remains Bullish On HCA Healthcare (HCA); Projects EBITDA Growth Of 2.8% and 4.6% in 2026 And 2027 HCA Healthcare, Inc. (NYSE:HCA), with a forward P/E of 12.27 and upside potential of 38.4%, is among the top 10 lowest forward P/E stocks in the S&P 500.
HCA Healthcare, Inc. (NYSE:HCA) is navigating a cautious macro backdrop for healthcare while continuing to invest in long-term workforce development
On June 4, 2026, Bernstein lowered its price target on HCA Healthcare, Inc. (NYSE:HCA) to $413 from $503, keeping a “Market Perform” rating. The firm said it views HCA as much more attractive at current valuation levels but does not expect a near-term catalyst to improve the outlook. Bernstein projects EBITDA growth of 2.8% in 2026 and 4.6% in 2027, citing lower insurance coverage from policy changes and a lack of growth in state-directed payments as the primary headwinds.
Meanwhile, on May 27, 2026, HCA Healthcare, Inc. (NYSE:HCA) announced an agreement to acquire The College of Health Care Professions (CHCP), one of the largest allied healthcare training providers in Texas. CHCP educates more than 8,000 students annually across 10 campuses in Texas and online, offering over 20 accredited programs, including Medical Assisting, Sonography, Surgical Technology, and Radiologic Technology. Financial terms were not disclosed.